Isis Pharmaceuticals (ISIS) initiates phase 2 studies evaluating ISIS-FXIRx in patients...

|By:, SA News Editor

Isis Pharmaceuticals (ISIS) initiates phase 2 studies evaluating ISIS-FXIRx in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty. The drug inhibits coagulation produced in the liver which is involved in the formation of clots, and the study will evaluate its effectiveness in reducing the number of thrombotic events - a potentially serious problem - in patients after surgery without increasing bleeding.